title: Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
authors.forename: Luciano
authors.initials: L
authors.lastname: Consuegra-Sánchez
authors.forename: Juan
authors.initials: J
authors.lastname: Sanchis
authors.forename: Julio
authors.initials: J
authors.lastname: Núñez
authors.forename: José Domingo
authors.initials: JD
authors.lastname: Cascón
authors.forename: Manuel
authors.initials: M
authors.lastname: Villegas
authors.forename: Francisco
authors.initials: F
authors.lastname: Picó
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000401:mortality*; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan